In an investigating study of 818 patients, the concentrations of blood GFAP are reported to be consistently increased in a stepwise pattern from preclinical AD, through mild cognitive impairment (MCI) to AD dementia compared to cognitively unimpaired (CU) individuals. This evidence concerns the gene GFAP and dementia.